Manufacturer of Controlled Substances; Notice of Registration, 57570-57571 [E6-16021]
Download as PDF
<![CDATA[
57570
Federal Register / Vol. 71, No. 189 / Friday, September 29, 2006 / Notices
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: September 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–16023 Filed 9–28–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on May 30,
2006, Abbott Laboratories, DBA Knoll
Pharmaceutical Company, 30 North
Jefferson Road, Whippany, New Jersey,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
Schedules I and II:
Drug
Schedule
jlentini on PROD1PC65 with NOTICES
Dihydromorphine (9145) ...............
Hydromorphone (9150) ................
I
II
The company plans to manufacture
bulk product and dosage units for
distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than November 28, 2006.
VerDate Aug<31>2005
20:43 Sep 28, 2006
Jkt 208001
Dated: September 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–16032 Filed 9–28–06; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
By Notice dated June 1, 2006, and
published in the Federal Register on
June 8, 2006, (71 FR 33315),
Mallinckrodt Inc., 3600 North Second
Street, St. Louis, Missouri 63147, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in Schedules I and II:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated May 17, 2006, and
published in the Federal Register on
May 25, 2006, (71 FR 30166), Lilly Del
Caribe, Inc., Chemical Plant, Kilometer
146.7, State Road 2, Mayaguez, Puerto
Rico 00680, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of
Dextropropoxyphene (9273), a basic
class of controlled substance listed in
Schedule II.
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Lilly
Del Caribe, Inc. to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Lilly Del Caribe, Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: September 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–16022 Filed 9–28–06; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00111
Fmt 4703
Sfmt 4703
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
Drug
Codeine-N-oxide (9053) ...............
Difenoxin (9168) ...........................
Dihydromorphine (9145) ...............
Morphine-N-oxide (9307) .............
Norlevorphanol (9634) ..................
Normorphine (9313) .....................
Tetrahydrocannabinols (7370) .....
Alfentanil (9737) ...........................
Amphetamine (1100) ....................
Ecgonine (9180) ...........................
Codeine (9050) .............................
Dextropropoxyphene, bulk (9273)
Dihydrocodeine (9120) .................
Diphenoxylate (9170) ...................
Diprenorphine (9058) ...................
Etorphine HCL (9059) ..................
Fentanyl (9801) ............................
Hydrocodone (9193) .....................
Hydromorphone (9150) ................
Levo-alphacetylmethadol (9648) ..
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Metopon (9260) ............................
Morphine (9300) ...........................
Nabilone (7379) ............................
Noroxymorphone (9668) ..............
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, granulated (9640) ............
Opium, powdered (9639) .............
Oxycodone (9143) ........................
Oxymorphone (9652) ...................
Phenazocine (9715) .....................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Thebaine (9333) ...........................
Schedule
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The firm plans to manufacture the
listed controlled substances for internal
use and for sale to other companies.
Since the publication of the Notice of
Application, it has been determined that
drug code 7360 (Marihuana) is not
needed as a bulk manufacturing drug
code for the company. The company has
subsequently withdrawn their request to
add this code to their current
application for registration.
E:\FR\FM\29SEN1.SGM
29SEN1
Federal Register / Vol. 71, No. 189 / Friday, September 29, 2006 / Notices
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Mallinckrodt Inc. to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Mallinckrodt Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: September 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–16021 Filed 9–28–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: September 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator,Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–16054 Filed 9–28–06; 8:45 am]
Dated: September 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–16020 Filed 9–28–06; 8:45 am]
BILLING CODE 4410–09–P
jlentini on PROD1PC65 with NOTICES
VerDate Aug<31>2005
20:43 Sep 28, 2006
Jkt 208001
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated May 17, 2006, and
published in the Federal Register on
May 25, 2006, (71 FR 30167), Stepan
Company, Natural Products Dept., 100
W. Hunter Avenue, Maywood, New
Jersey 07607, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
Schedule II:
Schedule
Cocaine (9041) .............................
Benzoylecgonine (9180) ...............
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Stepan Company to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Stepan Company to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
PO 00000
Frm 00112
Fmt 4703
Office of the Secretary
September, 21 2006.
DEPARTMENT OF JUSTICE
Drug
By Notice dated June 1, 2006, and
published in the Federal Register on
June 8, 2006, (71 FR 33316), Organix
Inc., 240 Salem Street, Woburn,
Massachusetts 01801, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Cocaine (9041),
a basic class of controlled substance
listed in Schedule II.
The company plans to manufacture a
chemical that is a derivative of cocaine
that will be sold to another company for
research purposes.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Organix Inc. to manufacture the listed
basic class of controlled substance is
consistent with the public interest at
this time. DEA has investigated Organix
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
DEPARTMENT OF LABOR
Submission for OMB Review:
Comment Request
BILLING CODE 4410–09–P
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
57571
Sfmt 4703
The Department of Labor (DOL) has
submitted the following public
information collection request (ICR) to
the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995 (Pub. L. 104–13,
44 U.S.C. Chapter 35). A copy of this
ICR, with applicable supporting
documentation, may be obtained by
contacting Ira Mills at the Department of
Labor on 202–693–4122 (this is not a
toll-free number) or e-mail:
Mills.Ira@dol.gov. This ICR can also be
accessed online at https://
www.doleta.gov/OMBCN/
OMBControlNumber.cfm.
Comments should be sent to Office of
Information and Regulatory Affairs,
Attn: OMB Desk Officer for ETA, Office
of Management and Budget, Room
10235, Washington, DC 20503, 202–
395–7316 (this is not a toll free number),
within 30 days from the date of this
publication in the Federal Register.
The OMB is particularly interested in
comments which:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
• Enhance the quality, utility and
clarity of the information to be
collected; and
• Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
Agency: Employment and Training
Administration (ETA).
E:\FR\FM\29SEN1.SGM
29SEN1
]]>Agencies
[Federal Register Volume 71, Number 189 (Friday, September 29, 2006)]
[Notices]
[Pages 57570-57571]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-16021]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated June 1, 2006, and published in the Federal Register
on June 8, 2006, (71 FR 33315), Mallinckrodt Inc., 3600 North Second
Street, St. Louis, Missouri 63147, made application by renewal to the
Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the basic classes of controlled substances listed in
Schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Codeine-N-oxide (9053)..................... I
Difenoxin (9168)........................... I
Dihydromorphine (9145)..................... I
Morphine-N-oxide (9307).................... I
Norlevorphanol (9634)...................... I
Normorphine (9313)......................... I
Tetrahydrocannabinols (7370)............... I
Alfentanil (9737).......................... II
Amphetamine (1100)......................... II
Ecgonine (9180)............................ II
Codeine (9050)............................. II
Dextropropoxyphene, bulk (9273)............ II
Dihydrocodeine (9120)...................... II
Diphenoxylate (9170)....................... II
Diprenorphine (9058)....................... II
Etorphine HCL (9059)....................... II
Fentanyl (9801)............................ II
Hydrocodone (9193)......................... II
Hydromorphone (9150)....................... II
Levo-alphacetylmethadol (9648)............. II
Levorphanol (9220)......................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Metopon (9260)............................. II
Morphine (9300)............................ II
Nabilone (7379)............................ II
Noroxymorphone (9668)...................... II
Opium extracts (9610)...................... II
Opium fluid extract (9620)................. II
Opium tincture (9630)...................... II
Opium, granulated (9640)................... II
Opium, powdered (9639)..................... II
Oxycodone (9143)........................... II
Oxymorphone (9652)......................... II
Phenazocine (9715)......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Thebaine (9333)............................ II
------------------------------------------------------------------------
The firm plans to manufacture the listed controlled substances for
internal use and for sale to other companies.
Since the publication of the Notice of Application, it has been
determined that drug code 7360 (Marihuana) is not needed as a bulk
manufacturing drug code for the company. The company has subsequently
withdrawn their request to add this code to their current application
for registration.
[[Page 57571]]
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Mallinckrodt Inc. to manufacture the listed basic classes of controlled
substances is consistent with the public interest at this time. DEA has
investigated Mallinckrodt Inc. to ensure that the company's
registration is consistent with the public interest. The investigation
has included inspection and testing of the company's physical security
systems, verification of the company's compliance with State and local
laws, and a review of the company's background and history. Therefore,
pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the
above named company is granted registration as a bulk manufacturer of
the basic classes of controlled substances listed.
Dated: September 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-16021 Filed 9-28-06; 8:45 am]
BILLING CODE 4410-09-P
